Key result
Autologous Treg therapy shows early potential to prevent CAV in pediatric heart transplant recipients.
Why the study?
Cardiac allograft vasculopathy limits long-term survival after paediatric heart transplant with no reversible treatment, prompting exploration of novel immunological approaches like regulatory T cell therapy.
Does autologous regulatory T cell (Treg) therapy prevent Cardiac Allograft Vasculopathy (CAV) in paediatric heart transplant recipients?
Does autologous regulatory T cell (Treg) therapy prevent Cardiac Allograft Vasculopathy (CAV) in paediatric heart transplant recipients?
Autologous regulatory T cell therapy represents a promising novel immunological approach to prevent cardiac allograft vasculopathy and reduce the burden of lifelong immunosuppression in paediatric heart transplant recipients.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in pediatric heart transplant recipients; hypothesis-generating for Treg therapy pending randomized trials.
Paediatric heart transplant is an established treatment for end stage heart failure in children, however patients have to commit to lifelong medical surveillance and adhere to daily immunosuppressants to minimise the risk of rejection. Compliance with immunosuppressants can be burdensome with their toxic side effects and need for frequent blood monitoring especially in children. Though the incidence of early rejection episodes has significantly improved overtime, the long-term allograft health and survival is determined by Cardiac Allograft Vasculopathy (CAV) which affects a vast number of post-transplant patients. Once CAV has set in, there is no medical or surgical treatment to reverse it and graft survival is significantly compromised across all age groups. Current treatment strategies include novel immunosuppressant agents and drugs to lower blood lipid levels to address the underlying immunological pathophysiology and to manage traditional cardiac risk factors. Translational researchers are seeking novel immunological approaches that can lead to permanent acceptance of the allograft such as using regulatory T cell (Tregs) immunotherapy. Clinical trials in the setting of graft versus host disease, autoimmunity and kidney and liver transplantation using Tregs have shown the feasibility and safety of this strategy. This review will summarise current knowledge of the latest clinical therapies for CAV and pre-clinical evidence in support of Treg therapy for CAV. We will also discuss the different Treg sources and the considerations of translating this into a feasible immunotherapy in clinical practice in the paediatric population.
No takes yet. Share an insight, caveat, or question.
Aiyengar et al. (2024) conducted a review in Cardiac Allograft Vasculopathy (CAV) in paediatric heart transplant recipients. Autologous regulatory T cell (Treg) therapy was evaluated. Autologous regulatory T cell therapy shows potential in pre-clinical and early clinical studies as a novel strategy to prevent cardiac allograft vasculopathy in pediatric heart transplant recipients.
Synapse has enriched 10 related papers. Consider them for comparative context: